{"id":"NCT03575351","sponsor":"Celgene","briefTitle":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","officialTitle":"A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-23","primaryCompletion":"2023-10-23","completion":"2023-10-23","firstPosted":"2018-07-02","resultsPosted":"2025-08-03","lastUpdate":"2025-08-03"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Non-Hodgkin"],"interventions":[{"type":"DRUG","name":"Standard of Care","otherNames":[]},{"type":"GENETIC","name":"JCAR017","otherNames":["lisocabtagene maraleucel or liso-cel"]}],"arms":[{"label":"Arm A - Standard of Care (SOC)","type":"ACTIVE_COMPARATOR"},{"label":"Arm B - JCAR017","type":"EXPERIMENTAL"}],"summary":"The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.\n\nThis is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive SOC (Arm A) or to receive JCAR017 (Arm B).\n\nAll subjects randomized to Arm A will receive Standard of care (SOC) salvage therapy (R-DHAP, RICE or R-GDP) as per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT).\n\nSubjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of an EFS event.\n\nSubjects randomized to Arm B will receive Lymphodepleting (LD) chemotherapy followed by JCAR017 infusion.","primaryOutcome":{"measure":"Event-free Survival (EFS) Per Independent Review Committee (IRC)","timeFrame":"From randomization to death from any cause, PD, failure to achieve CR or PR by 9 weeks post randomization, or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first (Up to 36 months)","effectByArm":[{"arm":"Standard of Care Arm","deltaMin":2.4,"sd":null},{"arm":"Liso-cel Arm","deltaMin":29.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States","Belgium","Finland","France","Germany","Italy","Japan","Netherlands","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["40623279","38547003","37544410","36542826","35717989","34515338","33288485"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":30},"commonTop":["Neutropenia","Anaemia","Thrombocytopenia","Nausea","Headache"]}}